RSV vaccination is recommend for pregnant women from 28 weeks

A single dose of the RSV vaccine Abrysvo is recommended for pregnant women between 28 and 36 weeks gestation to protect their newborns from severe RSV disease. The vaccine, which is free under the National Immunisation Program (NIP), triggers maternal antibodies that cross the placenta to provide protection for up to 6 months.
RSV infection in infants often causes lower respiratory tract disease, such as bronchiolitis. It is most likely to be severe during the first 6 months of life, frequently requiring hospitalisation. Maternal immunisation reduces the risk of severe RSV disease in infants. This is the result of passive protection by transplacental transfer of RSV-specific antibodies from the mother to the fetus during pregnancy.













